错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

  • Sidsel J. Juul,
  • Sára Rossetti,
  • Berthe M. P. Aleman,
  • Flora E. van Leeuwen,
  • Marleen A. E. van der Kaaij,
  • Francesco Giusti,
  • Paul Meijnders,
  • John M. M. Raemaekers,
  • Hanneke C. Kluin-Nelemans,
  • Michele Spina,
  • Daphne Krzisch,
  • Camille Bigenwald,
  • Aspasia Stamatoullas,
  • Marc André,
  • Wouter J. Plattel,
  • Martin Hutchings,
  • Maja V. Maraldo

摘要

Purpose

Studies looking into the concordance between late effects reported by physicians vs. those reported by Hodgkin lymphoma (HL) survivors are missing.

Methods

A Life Situation Questionnaire focusing on late effects collected data from 1230 HL survivors (median follow-up 14.3 years). Twenty-six disease- and treatment-related late effects from various organ systems were matched with physician-recorded data. The concordance between physicians and survivors was systematically evaluated using percentage agreement and kappa statistics. Potential non-responder biases and associations with patient and disease characteristics were also investigated.

Results

Agreement levels (indicated by kappa statistics) varied from none to moderate agreement, with the highest Kappa values observed for myocardial infarction (kappa = 0.55, 95% CI 0.43–0.66) and pulmonary embolism (kappa = 0.55, 95% CI 0.35–0.75). HL survivors consistently reported a higher prevalence of late effects compared with physicians. Notably, the prevalence of subjective symptoms such as persistent fatigue and xerostomia was repeatedly underreported by physicians. A trend towards higher concordance was observed in survivors with higher clinical stage, higher education level, and treatment initiated at younger ages. Additionally, findings indicated that survivors who did not respond to the questionnaire experienced fewer late effects compared to those who did respond.

Conclusions

Substantial discrepancies were noted in the reported prevalence of late effects between survivors and physicians, especially for outcomes which are not easily quantified.

Implications for Cancer Survivors

It is therefore essential to integrate outcomes reported by both physicians and survivors to achieve a comprehensive assessment of the long-term consequences of HL treatment.